Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S

Precision medicine has revolutionized the treatment of patients in EGFR driven non-small cell lung cancer (NSCLC). Targeted drugs show high response rates in genetically defined subsets of cancer patients and markedly increase their progression-free survival as compared to conventional chemotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Lategahn, Jonas, Keul, Marina, Klövekorn, Philip, Tumbrink, Hannah L., Niggenaber, Janina, Müller, Matthias P., Hodson, Luke, Flaßhoff, Maren, Hardick, Julia, Grabe, Tobias, Engel, Julian, Schultz-Fademrecht, Carsten, Baumann, Matthias, Ketzer, Julia, Mühlenberg, Thomas, Hiller, Wolf, Günther, Georgia, Unger, Anke, Müller, Heiko, Heimsoeth, Alena, Golz, Christopher, Blank-Landeshammer, Bernhard, Kollipara, Laxmikanth, Zahedi, René P., Strohmann, Carsten, Hengstler, Jan G., van Otterlo, Willem A. L., Bauer, Sebastian, Rauh, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2019
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886544/
https://www.ncbi.nlm.nih.gov/pubmed/31857889
http://dx.doi.org/10.1039/c9sc03445e

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886544/
https://www.ncbi.nlm.nih.gov/pubmed/31857889
http://dx.doi.org/10.1039/c9sc03445e

Ejemplares similares